

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Acotec Scientific Holdings Limited**  
**先瑞達醫療科技控股有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6669)**

**VOLUNTARY ANNOUNCEMENT**

**SUBMISSION OF AN IDE APPLICATION FOR ACOART LITOS™  
PACLITAXEL COATED PERCUTANEOUS TRANSLUMINAL  
ANGIOPLASTY (PTA) BALLOON CATHETER TO U.S. FDA**

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has recently submitted an Investigational Device Exemption (“**IDE**”) application for AcoArt Litos™ Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (the “**AcoArt Litos™**”) to the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (“**U.S. FDA**”).

**ABOUT THE ACOART LITOS™**

AcoArt Litos™ is a paclitaxel drug-coated balloons (DCB) used to prevent stenosis or occlusion in below-the-knee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. The Company received the CE Marking for AcoArt Litos™ in 2014, the U.S. FDA “breakthrough device” designation for AcoArt Litos™ in 2019 and the National Medical Products Administration (“**NMPA**”) approval for market for AcoArt Litos™ in December 2020, and successfully launched it in China in January 2021. According to Frost & Sullivan, AcoArt Litos™ is the first domestically manufactured device receiving U.S. FDA “breakthrough device” designation.

**There is no assurance that the AcoArt Litos™ will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Acotec Scientific Holdings Limited**  
**Jing LI**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, January 28, 2022

*As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.*